Table 3.
Concentration of MMPs, TIMP‐1, and sCD154 among different subtypes of MS with exacerbation (EC). Serum concentrations of these molecules were measured with an automated instrument, according to the manufacturer's instructions as described previously.
| MMP‐2 | MMP‐9 | TIMP‐1 | sCD154 | |
|---|---|---|---|---|
| RRMS with EC (n = 11) | 698.3 ± 165.3 | 684.2 ± 247.4 | 958.7 ± 111.5 | 4.7 ± 0.6 |
| SPMS with EC (n = 6) | 923.2 ± 109.8 | 967.4 ± 131.2 | 847.2 ± 285.2 | 6.1 ± 1.1 |
| Total patients with EC (n = 17) | 848.3 ± 123.5 | 784.2 ± 251.2 | 919.3 ± 190.3 | 5.2 ± 1.0 |
| Patients without EC (n = 38) | 810.2 ± 198.8 | 806.3 ± 224.3 | 938.0 ± 116.8 | 5.1 ± 1.5 |
| Significance (RRMS and SPMS; two tailed) | p = 0.0095* | p = 0.0206* | NS | p = 0.0037 * |
| Significance (total patients with EC and patients without EC; two tailed) | NS | NS | NS | NS |
Data are presented as mean (ng/mL) ± SD.
*Significant values.
EC = exacerbation; MMP = matrix metalloproteinase; MS = multiple sclerosis; NS = not significant; RRMS = relapsing‐remitting MS; sCD154 = soluble CD154; SD = standard deviation; SPMS = secondary‐progressive MS; TIMP‐1 = tissue inhibitor of metalloproteinase 1.